Only 1,000 UAE residents have received both doses of a Russian adenovirus-based Covid-19 vaccine as part of trials in the UAE.
Citing a report published by the Abu Dhabi Media Office, the vaccination phase for the trials has been completed and has been moved into the scientific data collection phase.
The findings during the trial will be combined with an existing global research finding, with interim results to be released next month.
So far, the said vaccine has shown a 91.6 percent efficacy rate against the deadly virus.
As part of the vaccine trial, the recipients will be monitored over 180 days.
The Russian vaccine has been developed by Gamaleya National Research Institute of Epidemiology and Microbiology, a public research institute in Russia, and facilitated in partnership with the Russian Direct Investment Fund.
“The clinical trials have shown promising results across the globe. This next stage will add important data, further demonstrating the high efficacy of the vaccine and strengthening the UAE’s global efforts in pioneering scientific discovery,” Kirill Dmitriev, RDIF chief executive officer said.